Israel - hebreu - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Israel - hebreu - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

Israel - hebreu - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Israel - hebreu - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Israel - hebreu - Ministry of Health

perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 25 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.

Israel - hebreu - Ministry of Health

vitamed pharmaceutical industries ltd - dexchlorpheniramine maleate; pseudoephedrine hydrochloride - סירופ - dexchlorpheniramine maleate 1 mg / 5 ml; pseudoephedrine hydrochloride 25 mg / 5 ml - pseudoephedrine, combinations - pseudoephedrine, combinations - relief of congestion in the respiratory tract due to allergy.

Israel - hebreu - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Israel - hebreu - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Israel - hebreu - Ministry of Health

padagis israel agencies ltd, israel - ferrous sulfate - טבליה - ferrous sulfate 247.25 mg - iron bivalent, oral preparations - prevention and treatment of iron deficiency anemia.

Israel - hebreu - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - תרחיף להזרקה - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.